Stengone Carmine N. — SEC Form 4 filings
SEC reporting owner CIK 1861519. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-08.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-05-29 to 2026-09-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,250 shares, $4,600 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 6 filings — 25,000 shares, $401,378 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 10,000 shares @ $16.01 ($160,080) in Contineum Therapeutics, Inc., filed 2026-07-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | CEO and President, Director | 9 | — | 7 legs · 25,000 sh · $401,378 | 19 |
| KIORA PHARMACEUTICALS INC (KPRX) | Director | 4 | 1 leg · 1,250 sh · $4,600 | — | 3 |
Form 4 filings — Stengone Carmine N.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 2,500 @ $1.01 · Sale (S): 2,500 @ $16.46 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 2,500 @ $1.01 · Sale (S): 2,500 @ $16.01 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 2,500 @ $1.01 · Sale (S): 2,500 @ $16 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 7,500 @ $1.01 · Option exercise (M): 2,500 @ $1.26 · Sale (S): 10,000 @ $16.01 · Option exercise (M): 7,500 (derivative) @ $0 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | KIORA PHARMACEUTICALS INC (KPRX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 4,400 @ $1.26 · Sale (S): 4,400 @ $16.02 · Option exercise (M): 2,700 @ $1.26 · Sale (S): 2,700 @ $16.02 · Option exercise (M): 4,400 (derivative) @ $0 · Option exercise (M): 2,700 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Contineum Therapeutics, Inc. (CTNM) | Option exercise (M): 400 @ $1.26 · Sale (S): 400 @ $16 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 445,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | KIORA PHARMACEUTICALS INC (KPRX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | KIORA PHARMACEUTICALS INC (KPRX) | Purchase (P): 1,250 @ $3.68 | EDGAR |
| 2024-07-03 | 4 | KIORA PHARMACEUTICALS INC (KPRX) | Grant/award (A): 1,778 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1861519 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →